


## Electronic Supplementary Material

### Development of A MERS-CoV Replicon Cell Line for Antiviral Screening

Jing Chen<sup>1,2</sup> • Bing-Jie Hu<sup>1,2</sup> • Kai Zhao<sup>1,2</sup> • Yun Luo<sup>1,2</sup> • Hao-Feng Lin<sup>1,2</sup> • Zheng-Li Shi<sup>1</sup>✉

1. CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China.
2. University of Chinese Academy of Sciences, Beijing 100049, China.

Supporting information to DOI: 10.1007/s12250-020-00341-z



**Fig. S1** Replication stability of the BHK21-MERS-Rep cell line. Luciferease activities of BHK21-MERS-Rep cells at different passage numbers were measured.